Clinical trials: C. Difficile
Diarrhea
Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease
The study will evaluate if administration of probiotic Culturelle (Lactobacillus Rhamnosus GG) along with antibiotics can help decrease the occurrence of diarrhea caused by antibiotics as well as Clostridium difficile Diarrhea.
- Trial name
- NCT02076438
- Testing
- Probiotics
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Clostridium Difficile, Clostridium Difficile Infection
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
To assess the association between Clostridium difficile (CD) toxins' serum levels and the grade of Clostridium difficile infection (CDI) severity/failure to CDI treatment and rate of recurrence.
- Trial name
- NCT03586206
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Roma Tre University
Clostridioides Difficile, Vancomycin Resistance Enterococcus Faecium
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
The purpose of this study is to evaluate the ability of oral vancomycin in preventing Clostridioides difficile infection (CDI) in patients that are simultaneously receiving antibiotics.
- Trial name
- NCT07221708
- Testing
- Vancomycin (POC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Clostridium Difficile
Fecal Transplant for Relapsing C. Difficile Infection
There has been an alarming increase in the incidence and severity of Clostridium difficile infection (CDI) in North America over the past decade.
- Trial name
- NCT01703494
- Testing
- Fecal Microbiota Transplantation
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Colleen Kelly
Intestinal C. Difficile
Probiotic Intervention With Elderly Subjects
The study objective is to evaluate the effect of probiotic on faecal Clostridium difficile levels of elderly subjects.
- Trial name
- NCT01475942
- Testing
- Probiotic
- Where
- Finland
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Danisco
Bacteria Infection Mechanism
Study of Factors Influencing the Dynamics of Colonisation and Decolonisation of the Digestive Tract by Clostridioides Difficile in Infants
Clostridioides difficile (formerly C. difficile) is a bacterium found in the form of spores (a resistant form) to which patients may be exposed in a hospital environment.
- Trial name
- BBDIFF (NCT07512908)
- Testing
- cohort follow up
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Hospital Infection, Standardized Antibiotic Prescribing Ratio (SAR)
InPART RX - Epicenters
InPART Rx is a collaborative research study to measure the impact of a planned quality improvement initiative to reduce unnecessary antibiotic prescribing by the Hospital Medicine Service through a process of receiving…
- Trial name
- InPART RX (NCT07368660)
- Testing
- Messaging Hospitalists, Usual Care
- Where
- 4 sites in United States
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Emory University
Clostridoides Difficile Associated Disease
To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults
An antibody is a substance your body makes to fight off infection. This study will explore the safety and antibody response of a vaccine to prevent severe diarrhea caused by a germ called Clostridoides difficile (C. diff).
- Trial name
- NCT05805826
- Testing
- C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2.
- Where
- 23 sites in United States
- Volunteers
- 936 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Colitis
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
The incidence of C. difficile infection (CDI) has alarmingly increased over the past several years and the affected population has expanded to include those previously at low risk, such as children.
- Trial name
- NCT01972334
- Testing
- FMT
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Clostridium Difficile Colitis
Phase I Trial of a Single Dose of CRS3123
Double-blind, randomized, placebo-controlled Phase I Trial to determine the safety and pharmokinetics of a single dose of CRS3123 in healthy adult volunteers.
- Trial name
- NCT01551004
- Testing
- CRS3123
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Recurrent C. Difficile Associated Diarrhea
Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea
The objective of the study is to investigate the efficacy of fresh, frozen or lyophilized fecal microbiota transplantation (FMT) via colonoscopy in patients with recurrent C. difficile associated diarrhea (RCDAD).
- Trial name
- NCT02318992
- Testing
- Fecal Microbiota
- Where
- United States
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Clostridium Difficile Infection Recurrence
Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections
The purpose of this study is to determine whether a single strain capsulated probiotic, when used after standard C. difficile antibiotic therapy, is effective in reducing the risk of infection recurrence mediated by a decrease in…
- Trial name
- NCT05606159
- Testing
- Bacillus velezensis DSM 33864
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novozymes A/S
Clostridium Difficile Infection
Pathogenic Mechanisms in C Diff Infection and Colitis
The purpose of this study is to learn more about infection by Clostridium difficile (also known as C. difficile). C. difficile is a common bacterium (a germ that may cause disease) that can live in the human gut.
- Trial name
- NCT01930032
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
C. Difficile, C. Difficile Infection
Clostridioides Difficile Controlled Human Infection Model
This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea.
- Conditions
- C. Difficile, C. Difficile Infection, Controlled Human Infection
- Trial name
- CloDiCHI (NCT06702345)
- Testing
- encapsulated 10^4 CFU toxigenic. C. difficile spores, Vancomycin, Clindamycin
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Clostridium Difficile Infection, Diarrhea
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
This study will further evaluate the ACAM-CDIFF™ vaccine in a population of middle-aged to elderly individuals at risk of exposure to Clostridium difficile because of impending hospitalization or residence in a care facility.
- Trial name
- NCT01230957
- Testing
- Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant)
- Where
- 30 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
The aim of this study was to evaluate the efficacy of the Clostridium difficile vaccine to prevent primary symptomatic C. difficile infection (CDI) in participants at risk for CDI where there is a substantial unmet medical need.
- Trial name
- NCT01887912
- Testing
- C. difficile Toxoid Vaccine
- Where
- 335 sites in United States, Australia and 24 more
- Volunteers
- 9,302 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile
Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis
This study was developed in response to the July, 2013 FDA draft guidance regarding FMT for CDI. The weight of the evidence in the literature suggests that FMT is the most effective treatment for ambulatory outpatients affected…
- Trial name
- NCT01973465
- Testing
- Stool
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OSF Healthcare System